Letendre, Scott (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137-42
|
Letendre, Scott L; Zheng, Jialin C; Kaul, Marcus et al. (2011) Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 17:63-9
|
Letendre, Scott L; Ellis, Ronald J; Ances, Beau M et al. (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45-55
|
Koopmans, P P; Ellis, R; Best, B M et al. (2009) Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med 67:206-11
|
Podzamczer, Daniel; King, Martin S; Klein, Cheri E et al. (2007) High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials 8:193-204
|
Letendre, Scott L; Woods, Steven P; Ellis, Ronald J et al. (2006) Lithium improves HIV-associated neurocognitive impairment. AIDS 20:1885-8
|
Letendre, Scott L; Cherner, Mariana; Ellis, Ronald J et al. (2005) The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19 Suppl 3:S72-8
|
Capparelli, Edmund V; Letendre, Scott L; Ellis, Ronald J et al. (2005) Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 49:2504-6
|
Capparelli, Edmund V; Holland, Diane; Okamoto, Charles et al. (2005) Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-52
|
Letendre, Scott; Marquie-Beck, Jennifer; Singh, Kumud K et al. (2004) The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol 157:193-6
|
Showing the most recent 10 out of 11 publications